Physician profile
Brian P Rajca
NPI 1083876197
$2,713.50
in general payments reported to CMS, 2019-2025
20 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $123 · 2022: $440 · 2023: $423 · 2024: $660 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,150.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,175.24 | 2021-2025 | |
| Genzyme Corporation | $226.24 | 2022-2025 | |
| Axonics, INC. | $160.80 | 2023-2024 | Axonics |
| Takeda Pharmaceuticals U.S.A., INC. | $146.01 | 2022-2025 | Entyvio |
| Janssen Biotech, INC. | $138.04 | 2023-2025 | Tremfya, Simponi Aria, Simponi |
| Phathom Pharmaceuticals, INC. | $130.06 | 2024-2025 | Voquezna |
| Fujifilm Healthcare Americas Corporation | $91.15 | 2023-2025 | Fujifilm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.27 | 2022-2025 | Xifaxan |
| Celgene Corporation | $84.85 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $78.95 | 2023-2025 | |
| Ardelyx, INC. | $73.47 | 2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $72.97 | 2022-2024 | Zeposia |
| Redhill Biopharma INC. | $68.61 | 2023-2024 | Talicia, Aemcolo |
| Biocon Biologics INC | $49.01 | 2025 | Yesintek |
| Regeneron Healthcare Solutions, INC. | $43.89 | 2024-2025 | Dupixent |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $21.43 | 2025 | Axonics |
| Celltrion USA INC. | $19.71 | 2024 | Vegzelma |
| Pfizer INC. | $17.88 | 2025 | |
| Nestle Healthcare Nutrition INC. | $14.56 | 2022 | |
| Aimmune Therapeutics, INC. | $13.36 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Rajca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.